Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. - Wikidata - awgldk - TriplyDB

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.

http://www.wikidata.org/entity/Q40547023

about

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma.Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.Standardized pretreatment inflammatory laboratory markers and calculated ratios in patients with oral squamous cell carcinoma.Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio.Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer.Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.Clinical Value of the Epstein-Barr Virus and p16 Status in Patients with Nasopharyngeal Carcinoma: A Single-Centre Study in Japan.Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis.Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: A meta-analysis.Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer.The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell cancer The C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma.Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis.Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for I Prognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma.Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients.The Lymphocyte-Monocyte Ratio and the Platelet-Lymphocyte Ratio at Diagnosis as Independent Prognostic Factors in Primary Gastrointestinal Diffuse Large B Cell Lymphoma.Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma.Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis.Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study

P2860

Q30235263-76351D1E-3FD2-4907-9205-B534AB35EC6D Q37465628-8B797FD7-0FF9-4BB6-B821-6ED63E99B963 Q37702050-DB09A034-8430-4ADA-87C5-DAAB5663F515 Q38901921-8AAF457E-B68A-4DA5-9133-EF437B9E2E87 Q39062109-C0D13831-239A-4A9E-8330-4BE46CC116ED Q39401725-13B9D209-7EDC-4A4F-84C5-3A6C11D8E530 Q40108064-EB710C0A-82E8-457D-B1C5-4E755CF77ACB Q40346047-39BADABF-CDEC-4044-9181-26315210367D Q41035366-33111B89-1509-4269-AAA1-E5C411EB2AA9 Q41091179-C3D37F9C-452B-403B-B382-E6066B0CD6F1 Q41278675-A2E0ECC7-B321-4ABA-936E-33BAEBAA6DF7 Q41694323-D3C2E0D4-7C60-409A-B72A-3C5B8F925411 Q42364956-196A88D5-975F-4D7F-AB04-31C31CE02791 Q42366562-C7BE4168-69A4-4D7A-B2F2-88F4613B2196 Q42371608-1A8477D8-8DEE-42AC-830B-0863C68B4CFC Q42377778-E64C316F-8881-458E-9206-ED0B064BA3FB Q47111490-A35DF8AF-20EC-473C-88FB-6570DA24C610 Q47630575-CECEFFD9-5351-42B8-B05D-03E8549684AE Q48212629-D5E1956B-5A05-4722-9F5A-304E4003745E Q54253295-3823090A-4AC7-4B0A-84A9-F0BD84E07D0E Q54967110-CDA88157-A1A2-4D48-8AA4-2C29851A3340 Q55279094-3E9E01A9-4418-416E-828E-7FD28C1D2F48 Q55340763-CA7D7875-6A51-4C1B-A378-7E2172CE5B37 Q57474616-3F8BBB84-A1A7-4A29-B433-7039313E7A6B

P2860

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.

http://www.wikidata.org/entity/Q40547023

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.

@en

type

label

Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.

@en

prefLabel

Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.

@en

P1433

Q40547023-1033ADFE-B76C-475B-AA49-72B45EC48445

P1476

Q40547023-C3B43FBB-B60A-4130-AFED-1C31F6C24BB7

P2093

Q40547023-16687F7B-23D6-4809-8457-5B071AB441B2

Q40547023-3106CF92-1E9C-44CC-BEC1-F8364BFE2B3A

Q40547023-36489B47-0D93-4CEB-B13E-FF42D41FDD48

Q40547023-49409F30-72E6-4394-BF2B-225F08435804

Q40547023-AE49A398-BA92-404A-A1A3-ABC5E53C59EF

Q40547023-B69FE3C6-1C0A-427E-9FC6-2605D104B478

Q40547023-C9A0D641-D19D-45AB-A9AD-1CE6350C3294

Q40547023-D7495FD6-F315-4835-B57E-8B3D86FA2B89

P2860

Q40547023-14F30C73-F7C7-45F9-A8C8-A8A8715B8DC7

Q40547023-159A32F3-980D-4F08-ABA1-097E423D161E

Q40547023-17A35ACF-C683-4AD3-9F49-FD9C46CD1D0A

Q40547023-189B4879-08D8-484A-90F6-0FF17956E485

Q40547023-18EDB024-3672-4FB6-B62D-6ECCB7ABCD4D

Q40547023-190DE584-AA61-4FA9-8BF9-7C33AF73DBB7

Q40547023-364BD0B3-6CEE-4FF7-B181-0F364B0BAA4C

Q40547023-3D238FD6-25B3-4CA9-B5E8-F2CB33E70421

Q40547023-48699318-EDFB-4178-85F1-D9472C3D9F33

Q40547023-4BAA6F7F-A2B8-4940-834A-A054F79AE425

P304

Q40547023-1951ACCC-44D1-4F97-BE66-59E6FD997902

P31

Q40547023-EB72C843-879C-427A-B92B-B821AB3F7903

P356

Q40547023-F1A2AB9A-7370-4869-8264-2832A226DA7B

P478

Q40547023-766B7CA5-C4B7-49F5-A366-9FFADD46F3B7

P577

Q40547023-8C44FA35-7748-485F-939A-C53188B21689

P698

Q40547023-FDA4C1DD-32E7-4E73-B01E-3A89D471F22F

P356

P1433

P1476

Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.

@en

P2093

Dongbo Liu

http://www.w3.org/2001/XMLSchema#string

Guangyuan Hu

http://www.w3.org/2001/XMLSchema#string

Guoqing Hu

http://www.w3.org/2001/XMLSchema#string

Guoxian Long

http://www.w3.org/2001/XMLSchema#string

Linli Zhang

http://www.w3.org/2001/XMLSchema#string

Min Luo

http://www.w3.org/2001/XMLSchema#string

Qi Mei

http://www.w3.org/2001/XMLSchema#string

Wei Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Immunity, Inflammation, and Cancer

The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients

Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma.

Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.

An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.

Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients

Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.

The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.

P304

E1332-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HED.24224

http://www.w3.org/2001/XMLSchema#string

P478

38 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26362911

http://www.w3.org/2001/XMLSchema#string